FMR LLC Reports 9.63% Stake in Regeneron Pharma
Ticker: REGN · Form: SC 13G/A · Filed: Feb 9, 2024 · CIK: 872589
| Field | Detail |
|---|---|
| Company | Regeneron Pharmaceuticals, Inc. (REGN) |
| Form Type | SC 13G/A |
| Filed Date | Feb 9, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, pharmaceuticals
TL;DR
**FMR LLC still owns 9.63% of Regeneron, a strong institutional vote of confidence.**
AI Summary
FMR LLC, a major investment firm, and its principal owner, Abigail P. Johnson, have updated their ownership stake in Regeneron Pharmaceuticals Inc. As of December 31, 2023, they collectively beneficially own 10,317,407 shares of common stock, representing 9.630% of the company. This is an amendment (Amendment No. 5) to a previous filing, indicating a slight adjustment in their reported holdings. This matters to investors because FMR LLC is a significant institutional holder, and changes in their reported stake can signal their ongoing confidence (or lack thereof) in Regeneron's future prospects.
Why It Matters
This filing shows that a major institutional investor, FMR LLC, maintains a substantial stake in Regeneron, which can be seen as a vote of confidence in the company's long-term value.
Risk Assessment
Risk Level: low — This filing indicates a stable, significant institutional ownership, which generally reduces volatility and provides a degree of stability.
Analyst Insight
Investors should note that a major institutional holder like FMR LLC maintains a substantial position, suggesting continued confidence in Regeneron. While not a direct buy signal, it provides a positive data point for long-term holders.
Key Numbers
- 10,317,407 — Shares Beneficially Owned (Represents the total common stock shares of Regeneron Pharmaceuticals Inc. held by FMR LLC and Abigail P. Johnson.)
- 9.630% — Percent of Class (Indicates the proportion of Regeneron's common stock owned by FMR LLC and Abigail P. Johnson, showing their significant stake.)
Key Players & Entities
- FMR LLC (company) — reporting person and parent holding company
- Abigail P. Johnson (person) — reporting person, principal owner of FMR LLC
- REGENERON PHARMACEUTICALS, INC. (company) — subject company, issuer of the securities
- 10,317,407 (dollar_amount) — total shares beneficially owned by FMR LLC and Abigail P. Johnson
- 9.630% (dollar_amount) — percentage of class beneficially owned
Forward-Looking Statements
- FMR LLC will maintain a significant, albeit potentially fluctuating, stake in Regeneron Pharmaceuticals Inc. over the next year. (FMR LLC) — high confidence, target: 2025-02-09
FAQ
Who are the reporting persons in this SC 13G/A filing?
The reporting persons are FMR LLC and Abigail P. Johnson, as stated in Item 1 for both entities.
What is the total number of shares of Regeneron Pharmaceuticals Inc. common stock beneficially owned by FMR LLC and Abigail P. Johnson?
FMR LLC and Abigail P. Johnson each beneficially own 10,317,407 shares of common stock, as indicated in Item 7 and Item 9 for both reporting persons.
What percentage of Regeneron Pharmaceuticals Inc.'s common stock do FMR LLC and Abigail P. Johnson collectively own?
They collectively own 9.630% of the class of common stock, as stated in Item 11 for both FMR LLC and Abigail P. Johnson, and in Item 4(b) for FMR LLC.
What is the CUSIP number for Regeneron Pharmaceuticals Inc. common stock mentioned in the filing?
The CUSIP number is 75886F107, as listed under 'Cusip #75886F107' at the beginning of the filing and in Item 2(e).
What rule is this Schedule 13G/A filed under?
This Schedule 13G/A is filed under Rule 13d-1(b), as indicated by the checked box '[x] Rule 13d-1(b)' and further explained in Item 3.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on February 9, 2024 by Abigail P. Johnson regarding REGENERON PHARMACEUTICALS, INC. (REGN).